Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
grade A 19.55 4.83% 0.90
CHRS closed up 4.83 percent on Monday, June 17, 2019, on 89 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical CHRS trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Up 3 Days in a Row Strength 4.83%
Up 4 Days in a Row Strength 4.83%
New Uptrend Bullish 7.12%
Up 3 Days in a Row Strength 7.12%
Oversold Stochastic Weakness 7.12%

Older signals for CHRS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Medicine Biotechnology Biopharmaceutical Immunology Chemotherapy Breast Cancer Rheumatoid Arthritis Psoriasis Immunosuppressants Biosimilar Recombinant Proteins Treatment Of Breast Cancer Etanercept
Is CHRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.18
52 Week Low 8.32
Average Volume 915,714
200-Day Moving Average 14.1916
50-Day Moving Average 16.995
20-Day Moving Average 18.9015
10-Day Moving Average 18.233
Average True Range 0.9023
ADX 26.59
+DI 26.805
-DI 15.2546
Chandelier Exit (Long, 3 ATRs ) 18.4731
Chandelier Exit (Short, 3 ATRs ) 19.7569
Upper Bollinger Band 20.7698
Lower Bollinger Band 17.0332
Percent B (%b) 0.67
BandWidth 19.768801
MACD Line 0.3496
MACD Signal Line 0.449
MACD Histogram -0.0993
Fundamentals Value
Market Cap 1 Billion
Num Shares 51.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -7.52
Price-to-Sales 3.37
Price-to-Book 17.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.31
Resistance 3 (R3) 21.16 20.43 21.01
Resistance 2 (R2) 20.43 19.98 20.50 20.91
Resistance 1 (R1) 19.99 19.71 20.21 20.14 20.82
Pivot Point 19.26 19.26 19.37 19.33 19.26
Support 1 (S1) 18.82 18.81 19.04 18.97 18.28
Support 2 (S2) 18.09 18.54 18.16 18.19
Support 3 (S3) 17.65 18.09 18.09
Support 4 (S4) 17.80